We observed that Ibrutinib was capable of significantly counteracting the in vitro generation of large mature osteoclasts, which was enhanced by the addition of CLL-cm in the culture of RANKL-activated monocytes [7]. The gene discussed is TNFSF11; the disease is B-cell chronic lymphocytic leukemia.